(Reuters) - The Food and Drug Administration panel of outside cancer experts urged the agency to make marketing of the medicines contingent upon further restrictions being placed on the drugs' labels and upon an agreement by the companies to conduct more clinical trials.
The FDA usually, but not always, follows the recommendations of its advisers.
Read more at Reuters.com Government Filings News
Subscribe to:
Post Comments (Atom)
No comments:
Post a Comment